Sunshine Biopharma Q2 revenue $9.3M (+67% YoY); net loss narrows 45% to $(494K)

Sunshine Biopharma Inc.

2025-Q2 EPS reported -$43.48 vs consensus -$0.11 ▼ miss (-38652.2%)

Q2 gross revenue $9,303,067, up 67% from $5,560,865 in Q2 2023.
Net loss for Q2 2024 was $(494,300) vs $(902,108) in Q2 2023, a 45% improvement.
YTD revenue $16,844,113, up 61% from $10,454,918; YTD net loss $(1,778,101) improved 32%.
Sequential Q2 sales grew 23% over Q1 2024 sales of $7,541,046.
Shareholders' equity $23,489,865, up 11% from Dec 31, 2023.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.